合并使用利培酮治疗难治性抑郁症的临床研究

目的：探讨抗抑郁剂合并使用利培酮治疗难治性抑郁症的疗效。方法：随机将47例难治性抑郁症患者分为研究组和对照组，其中研究组23例，有原抗抑郁药不变的同时合并使用利培酮；对照组24例，维持原抗抑郁药不变，治疗4周，使用汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）进行疗效评定。结果：治疗1周末时研究组HAMD减分率显示有8．7％的患者（2例）获临床痊愈或显著进步，而对照组减分率无统计学差异；4周末，研究组临床痊愈或显著进步为39．1％（9例），进步为17．4％（4例），总有效率为56．5％；而对照组相应为12．5％（3例），8．3％（2例），总有效率为20．8％。结论：难治性抑郁症患者在常规使用抗抑郁药的同时合并使用利培酮是一种有效的策略之一。

Risperidone augmentation of antidepressants in treatment-resistant depression

Objective:To explore the efficacy of risperidone augmention of antidepressants in treatment-resistant depression. Methods:47 patients with treatment-resistant depression were randomly divided into two groups: study group(23 cases) and control group(24 cases).Patients in study group were treated with risperidone(1-4mg) augmentation of ongoing antidepressant for 4 weeks;patients in control group treated with ongoing antidepressant.All subject were evaluated with Hamilton depression scale(HAMD) and Hamilton anxiety scale(HAMA).Results: 2 patients in study group remitted after 1week.After 4 weeks,9(39.1%) cases of study group had recovery or marked improvement,4(17.4%) had improvement,the total response rate was 56.5%;for control group,only 3(12.5%) had marked improvement or recovery,2(8.3%) had improvement,the total response rate was 20.8%.Conclusions: Risperidone augmentation may be a effective strategy for treatment-resistant depression.